Cullinan Therapeutics' Zipalertinib Fails to Meet Expectations in Phase III REZILIENT3 Trial

Cullinan Therapeutics reported results from the Phase III REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival for zipalertinib plus chemotherapy versus chemotherapy alone. Cullinan's stock (CGEM) may see a positive reaction in the market.